A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Background: Schedules with ...
PHOENIX, AZ, Jan 26, 2015 (Marketwired via COMTEX) -- Insys Therapeutics, Inc. INSY, +0.10% a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug ...
A recent article published in Applied Surface Science Advances describes the bioprinting of nanostructured patches composed of sodium alginate (NaAlg), polyvinyl alcohol (PVA), and indocyanine green ...
SAN DIEGO--(BUSINESS WIRE)--Cymbiotika, a leading dietary supplement brand known for creating pure, clinically backed supplements, announced today the release of Liposomal Sulforaphane Matrix to ...
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback